Protalix BioTherapeutics (NYSE:PLX – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares Protalix BioTherapeutics and Gilead Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protalix BioTherapeutics | $80.62 million | 2.72 | $8.31 million | $0.23 | 11.83 |
| Gilead Sciences | $30.46 billion | 6.14 | $8.51 billion | ($2.67) | -56.53 |
Volatility and Risk
Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.
Profitability
This table compares Protalix BioTherapeutics and Gilead Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
| Gilead Sciences | -10.64% | -2.11% | -0.75% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Protalix BioTherapeutics and Gilead Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Gilead Sciences | 0 | 5 | 23 | 1 | 2.86 |
Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 341.18%. Gilead Sciences has a consensus price target of $158.78, suggesting a potential upside of 5.20%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Gilead Sciences.
Insider & Institutional Ownership
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Gilead Sciences beats Protalix BioTherapeutics on 10 of the 15 factors compared between the two stocks.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
